HighIDH1expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia

IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo

(2014) Ju-Bo Wang et al.   Asian Pacific Journal of Cancer Prevention

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

(2014) W.-L. Chen et al.   BLOOD

Prognostic Role of MicroRNA-181a/b in Hematological Malignancies: A Meta-Analysis

(2013) Shenglong Lin et al.   PLoS One

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China

(2013) J.-H. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities

(2013) R. A. Cairns et al.   Cancer Discovery

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

(2012) G. Jin et al.   CANCER RESEARCH

miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes

(2012) Dan-Xia Zhu et al.   CARCINOGENESIS

Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?

(2012) Ralph J. DeBerardinis et al.   CELL

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

(2012) H. Yang et al.   CLINICAL CANCER RESEARCH

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

(2012) M. Sasaki et al.   GENES & DEVELOPMENT

Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive Carboxylation

(2012) Roberta Leonardi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Potential application ofIDH1andIDH2mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

(2012) Kuang-Guo Zhou et al.   LEUKEMIA & LYMPHOMA

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

(2011) N. Boissel et al.   BLOOD

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2

(2011) Alexandra Borodovsky et al.   CURRENT OPINION IN ONCOLOGY

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

(2010) F. Thol et al.   BLOOD

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. Schwind et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Prognostic Importance ofMN1Transcript Levels, and Biologic Insights FromMN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2009) Christian Langer et al.   JOURNAL OF CLINICAL ONCOLOGY

ERGExpression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis ofERG, MN1, andBAALCTranscript Levels Using Oligonucleotide Microarrays

(2009) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

(2008) C. Langer et al.   BLOOD

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Guido Marcucci et al.   NEW ENGLAND JOURNAL OF MEDICINE